COMPANY PRESENTS AT THOMAS WEISEL WEDNESDAY, SEPTEMBER 3RD AND NEWSMAKERS
IN THE BIOTECH INDUSTRY CONFERENCE THURSDAY, SEPTEMBER 4TH
SAN DIEGO, Aug. 25 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer will be presenting at both the Thomas Weisel Healthcare Conference in Boston and the NewsMakers in the Biotech Industry Conference in New York.
The presentation at the Thomas Weisel Conference in Boston at the Four Seasons takes place Wednesday, September 3, 2008 at 2:05 p.m. Eastern Time (ET) / 11:05 a.m. Pacific Time (PT). The live presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com.
The presentation at the NewsMakers in the Biotech Industry Conference in New York at the Millennium Broadway will take place Thursday, September 4, 2008 at 10:00 a.m. Eastern Time (ET) / 7:00 a.m. Pacific Time (PT). The live presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com.
If you are unable to attend these webcasts and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentations to download or install any necessary software. A replay of both presentations will be available approximately one hour after the conclusion of the live event and will be archived on the Company's website for two weeks.
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.
|SOURCE Neurocrine Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved